No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC

In fact, the worst survival outcomes were seen with the most commonly used first-line regimen, FOLFOX chemotherapy plus the VEGF inhibitor bevacizumab.
Medscape Medical News